Biomedical subjects

Salete Benetton

Publications and source records attributed to Salete Benetton.

3 recordsLinked to original sources

PubMed2006

Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer.

Metabolic activation of pradefovir to 9-(2-phosphonylmethoxyethyl)adenine (PMEA) was evaluated by using cDNA-expressed CYP isozymes in portal vein-cannulated rats following oral administration and in human liver microsomes. The enzyme induction potential of pradefovir was evaluated in rats following multiple oral dosing and in primary cultures of human hepatocytes. The results indicated that CYP3A4 is the only cDNA-expressed CYP isozyme catalyzing the conversion of pradefovir to PMEA. Pradefovir was converted to PMEA in human liver microsomes with a K(m) of 60 microM, a maximum rate of metabolism of 228 pmol/min/mg protein, and an intrinsic clearance of about 359 ml/min. Addition of ketoconazole and monoclonal antibody 3A4 significantly inhibits the conversion of pradefovir to PMEA in human liver microsomes, suggesting the predominant role of CYP3A4 in the metabolic activation of pradefovir. Pradefovir at 0.2, 2, and 20 microM was neither a direct inhibitor nor a mechanism-based inhibitor of CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP2E1, and CYP1A2 in human liver microsomes. In rats, the liver was the site of metabolic activation of pradefovir, whereas the small intestine did not play a significant role in the metabolic conversion of pradefovir to PMEA. Daily oral dosing (300 mg/kg of body weight) to rats for 8 days showed that pradefovir was not an inducer of P450 enzymes in rats. Furthermore, pradefovir at 10 microg/ml was not an inducer of either CYP1A2 or CYP3A4/5 in primary cultures of human hepatocytes.

Adenine↗

PubMed2003

Chip-based P450 drug metabolism coupled to electrospray ionization-mass spectrometry detection.

A chip-based P450 in vitro metabolism assay coupled with ESI-MS and ESI-MS/MS detection is described in this paper. The chips were made of a cyclic olefin polymer using a hot embossing process. The introduction of reagent solutions into the chip was carried out using fused-silica capillaries coupled to two syringes with the flow rate controlled by a syringe pump. Initial experiments described here employed a small commercial guard column in an off-chip format to desalt and concentrate the products of the enzymatic reaction prior to ESI-MS analysis. The system was used both to yield the Michaelis constant (K(m)) of the P450 biotransformation of imipramine into desipramine and to determine the IC50 value of a chemical inhibitor (tranylcypromine) for this CYP2C19-mediated reaction. The results demonstrated that the kinetics of the reaction inside the 4-microL volume within the channels of the cyclic olefin polymer chip provided results in agreement with those reported in the literature using conventional assays. The above reactions were carried out using human liver microsomes, and the metabolites were detected by ESI-MS showing the potential of the chip-based P450 reaction for metabolite screening studies as well as for P450 inhibition assays. A porous monolithic column was subsequently integrated into the chip to perform the reaction mixture cleanup process in an integrated fashion on the chip that is necessary for ESI-MS detection. The miniature monolithic SPE column was prepared in situ inside the chip via UV-initiated polymerization. The results obtained using the integrated system demonstrated the possibility of performing P450 enzymatic reactions in a microvolume reaction chamber coupled directly to ESI-MS detection and required less than 4 microg of HLM protein.

Alkenes↗

PubMed2003

Chip-based solid-phase extraction pretreatment for direct electrospray mass spectrometry analysis using an array of monolithic columns in a polymeric substrate.

An array of eight porous monolithic columns, prepared in a Zeonor polymeric chip by UV-initiated polymerization of butyl methacrylate and ethylene dimethacrylate, was tested for solid-phase extraction (SPE) cleanup of biological samples prior to directly coupled electrospray mass spectrometry (ESI-MS). The chip, fabricated by hot embossing and thermal bonding, consists of eight parallel channels (10 mm long, 360 microm i.d.) connected via external fused-silica capillaries. The monomer mixture was aspirated simultaneously into the eight channels using a homemade vacuum manifold device and polymerized in parallel for 20 min under UV irradiation. The porous monolithic columns were then characterized by scanning electron microscopy and evaluated by ESI-MS applications with respect to sample capacity, recovery, reproducibility of peak area or peak height ratios, and linearity between peak height ratio and concentration using imipramine as a pharmaceutical test compound. The average sample capacity was estimated to be 0.30 microg with a relative standard deviation (RSD) of 26.5% for the eight monolithic columns on the same polymeric chip. For two chips prepared using the same monomer mixture, the difference in average sample capacity was 7.0%. The average recovery for the eight monolithic SPE columns on the same chip was 79.1% with an RSD of 7.9%. Using imipramine-d3 as an internal standard, the RSD of peak height ratios for the eight different columns was 2.0% for a standard solution containing 1 microg/mL imipramine. A linear calibration curve (R2 = 0.9995) was obtained for standard aqueous solutions of imipramine in the range from 0.025 to 10 microg/mL. To demonstrate the analytical potential of the chip-based SPE system, two different types of real-world samples including human urine sample and P450 drug metabolism incubation mixture were tested. Similar to standard aqueous solution, a linear correlation (R2 = 0.9995) was also found for human urine sample spiked with imipramine in the range of 0.025-10 microg/ mL. When aliquots of a human urine sample spiked with 1 microg/mL imipramine were loaded onto eight different monolithic columns, the RSD of peak height ratios was 3.8%. For a P450-imipramine incubation mixture, the formation of the N-demethylated metabolite (m/z 267.2) and the monohydroxylated metabolite (m/z 297.2) of imipramine was observed following chip-based monolithic SPE sample cleanup and preconcentration.

Journal Article↗